0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Protein > HLA-A*02:01 & B2M & NY-ESO-1 > HL1-H52E8

Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein (MALS & SPR verified)

Streptavidin Protein - PE (STN-NP117, STN-NP119), supporting the assembly of your own MHC Tetramers!

Order Now

  • Synonym
    HLA-A*02:01 & B2M & NY-ESO-1
  • Source
    Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein(HL1-H52E8) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & SLLMWITQC peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769 (B2M) & SLLMWITQC).
    Predicted N-terminus: Gly 25 & Ser
  • Molecular Characterization

    Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein is assembled by biotinylated monomer (HL1-H82E6) and streptavidin.

    Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein is produced by co-expression of HLA and B2M loaded with NY-ESO-1 peptide. Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 36.3 kDa, 13.8 kDa and 13.3 kDa. The protein migrates as 43-47 kDa, 15 kDa and 14 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >90% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
HLA-A*02:01 & B2M & NY-ESO-1 SDS-PAGE

Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS
HLA-A*02:01 & B2M & NY-ESO-1 MALS images

The purity of Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein (Cat. No. HL1-H52E8) is more than 90% and the molecular weight of this protein is around 260-290 kDa verified by SEC-MALS.

Bioactivity-ELISA
 HLA-A*02:01 & B2M & NY-ESO-1 ELISA

Immobilized Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein (Cat. No. HL1-H52E8) at 5 μg/mL (100 μL/well) can bind Anti-NY-ESO-1 Antibody, Human IgG1 with a linear range of 0.001-0.313 μg/mL (QC tested).

 HLA-A*02:01 & B2M & NY-ESO-1 ELISA

Immobilized Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein (Cat. No. HL1-H52E8) at 1 μg/mL (100 μL/well) can bind Anti-B2M Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (Routinely tested).

Bioactivity-SPR
 HLA-A*02:01 & B2M & NY-ESO-1 SPR

Anti-NY-ESO-1 antibody captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein (Cat. No. HL1-H52E8) with an affinity constant of 1.35 nM as determined in a SPR assay (Biacore 8K) (QC tested).

 HLA-A*02:01 & B2M & NY-ESO-1 SPR

NY-ESO-1 TCR captured on Protein A Chip can bind Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (Cat. No. HL1-H52E7) with an affinity constant of 15.7 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

  • Background
    NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A*0201 NY-ESO-1 (SLLMWITQC) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and SLLMWITQC peptide of the NY-ESO-1.
  • Clinical and Translational Updates

Comments (0)


ETA des produits en stock: 2 jours ouvrables

Price(EUR) : €280.00

Price(EUR) : €1780.00

Promotion & Exhibitions



Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Laisser un message